| Registry | NCT07566975 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 50 (Estimated) |
| Sponsor | Neuro-Ophthalmology of Texas (Other); collaborators: Harrow Inc |
| Conditions | Dry Eye |
| Interventions | Cyclosporine ophthalmic solution 0.1% (Other) |
| Dates | start 2026-03-31, primary completion 2026-11-30 (estimated), completion 2026-11-30 (estimated), first posted 2026-05-05, last updated 2026-05-05 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Dry Eye All trials of Cyclosporine ophthalmic solution 0.1%
patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Dry Eye without neurotrophic changes | Other: Cyclosporine ophthalmic solution 0.1% | ||
| Dry Eye with neurotrophic changes | Other: Cyclosporine ophthalmic solution 0.1% |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires Exclusion Criteria: * Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring / zero sensitivity
| Facility | City | Country | Status |
|---|---|---|---|
| Neuro Ophthalmology of TX | Houston, Texas | United States | Recruiting |